Dualitas Therapeutics Launches with $65 Million Series A Financing

Dualitas Therapeutics, a biotechnology company pioneering next-generation bispecific antibody (BsAb) therapies, has launched from stealth mode with a $65 million Series A financing. The funding was co-led by Versant Ventures and Qiming Venture Partners USA, with participation from founding investor SV Health Investors and new strategic investors Chugai Venture Fund, Eli Lilly and Company, and Alexandria Venture Investments. The funds will be used to advance a portfolio of next-generation bispecific antibodies, including lead programs DTX-103 in allergic disease and DTX-102 for autoimmune disease, and to accelerate the development of Dualitas' proprietary DualScreen TM BsAb discovery engine.

Key Takeaways:

• Dualitas Therapeutics has launched with a $65 million Series A financing, co-led by Versant Ventures and Qiming Venture Partners USA.
• The company is pioneering next-generation bispecific antibody (BsAb) therapies for immunology and inflammation (I&I) using its proprietary DualScreen TM discovery engine.
• Lead programs DTX-103 and DTX-102 have generated compelling preclinical data when benchmarked against approved therapies for allergic and autoimmune diseases, respectively.
• Dualitas' DualScreen TM discovery engine uniquely identifies novel bispecific antibody candidates with differentiating biology, including via cell-surface proximity mechanisms.
• The company has a team of experienced drug developers, biotherapeutic engineers, immunologists, and business leaders with a proven track record in developing antibody technologies from preclinical stages through product approvals.
• Dualitas plans to advance a pipeline that capitalizes on cell-surface proximity biology mechanisms and pursue strategic partnerships to extend the reach and impact of DualScreen-discovered candidates.

Statistics:

• $65 million: The amount of Series A financing secured by Dualitas Therapeutics.
• 2: The number of lead programs in Dualitas' pipeline, targeting allergic diseases (DTX-103) and autoimmune diseases (DTX-102).
• 10: The number of years of combined experience in drug development among Dualitas' senior management team.
• 5: The number of strategic investors participating in the Series A financing.

Sources:

• PR Newswire: "Dualitas Therapeutics Launches with $65 Million Series A Financing" (September 16, 2025)
• Dualitas Therapeutics: "Dualitas Therapeutics Launches with $65 Million Series A Financing" (press release)
• Versant Ventures: "Versant Ventures Leads $65 Million Series A Financing in Dualitas Therapeutics" (press release)
• Qiming Venture Partners USA: "Qiming Venture Partners USA Co-Leads $65 Million Series A Financing in Dualitas Therapeutics" (press release)